MedTrace Logo

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

NCT00621725 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-07-15

No results posted yet for this study

Summary

To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.

Conditions

Interventions

DRUG

AZD2171

Oral dose

Sponsors & Collaborators

Principal Investigators

  • CML van Herpen, MD · Radboud University Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-07-31
Completion
2014-01-31

Countries

  • Denmark
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621725 on ClinicalTrials.gov